EFFICACY AND SAFETY OF INTRAVENOUS USTEKINUMAB RE-INDUCTION THERAPY IN CROHN'S DISEASE PATIENTS WITH SECONDARY LOSS OF RESPONSE TO USTEKINUMAB MAINTENANCE THERAPY: WEEK 16 RESULTS FROM THE POWER TRIAL

被引：0
|
作者：
Lee, Scott D.
Schreiber, Stefan
Janneke, Christien
Van der Woude
Marin-Jimenez, Ignacio
Wolf, Douglas C.
Schnoy, Elisabeth
Salzberg, Bruce
Busse, Christopher
Nazar, Maciej
Langholff, Wayne
Borghorst, Stephan
Gasink, Christopher
Baker, Thomas
Godwin, Bridget
Feagan, Brian G.
机构：
来源：
GASTROENTEROLOGY | 2023年 / 164卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1027
引用
收藏
页码：S220 / S220
页数：1
相关论文
共 50 条
  • [31] Clinical and endoscopic response to ustekinumab in Crohn's disease: Week 16 interim analysis of the STARDUST trial
    Danese, S.
    Vermeire, S.
    D'Haens, G.
    Panes, J.
    Dignass, A.
    Magro, F.
    Nazar, M.
    Le Bars, M.
    Sloan, S.
    Lahaye, M.
    Ni, L.
    Daperno, M.
    Lukas, M.
    Armuzzi, A.
    Lowenberg, M.
    Gaya, D. R.
    Peyrin-Biroulet, L.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S049 - S052
  • [32] Concentrations of Ustekinumab During Induction Therapy Associate With Remission in Patients With Crohn's Disease
    Soufflet, Ninon
    Boschetti, Gilles
    Roblin, Xavier
    Cuercq, Charlotte
    Williet, Nicolas
    Charlois, Anne-Laure
    Duclaux-Loras, Remi
    Danion, Pauline
    Mialon, Anne
    Faure, Mathias
    Paul, Stephane
    Flourie, Bernard
    Nancey, Stephane
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 17 (12) : 2610 - 2612
  • [33] Case Series: Re-induction of Intravenous, Weight-Based Ustekinumab Is Well Tolerated in Patients With Moderate-Severe Crohn's Disease
    Lee, Scott David
    Kamp, Kendra
    Clark-Snustad, Kindra Dawn
    CROHNS & COLITIS 360, 2022, 4 (02)
  • [34] Efficacy and Safety of Ustekinumab Therapy in Crohn's Disease: A Systematic Review and Meta-Analysis
    Malik, Adnan
    Nadeem, Mahum
    Haider, Maryam
    Amjad, Waseem
    Naseem, Khadija
    Malik, Muhammad
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S1372 - S1372
  • [35] Efficacy and safety of ustekinumab in the induction therapy of TNF-α-refractory Crohn's disease patients: a systematic review and meta-analysis
    Kawalec, Pawel
    Mocko, Pawel
    Malinowska-Lipien, Iwona
    Brzostek, Tomasz
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2017, 6 (07) : 601 - 612
  • [36] Response to Ustekinumab Therapy Is Associated with an Improvement of Nutritional Status in Patients with Crohn's Disease
    Bertani, Lorenzo
    DAlessandro, Claudia
    Fornili, Marco
    Coppini, Francesca
    Zanzi, Federico
    Carmisciano, Luca
    Geri, Francesca
    Svizzero, Giovanni Baiano
    Rosi, Emma Maria
    De Bernardi, Alice
    Ceccarelli, Linda
    Mumolo, Maria Gloria
    Baglietto, Laura
    Bellini, Massimo
    De Bortoli, Nicola
    Costa, Francesco
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (19)
  • [37] Ustekinumab in pediatric patients with Crohn's disease: safety, and efficacy results from a multicenter retrospective study in China
    Li, Ping
    Wang, Lin
    Tang, Zifei
    Wang, Yuhuan
    Liu, Zhanju
    Ge, Wensong
    Huang, Ying
    FRONTIERS IN PEDIATRICS, 2024, 12
  • [38] Efficacy and Safety of Dose Adjustment and Delayed Response to Ustekinumab in Moderate - Severe Crohn's Disease Patients: Results from the IM-UNITI Maintenance Study
    Sands, Bruce
    Gasink, Chris
    Jacobstein, Doug
    Gao, Long Long
    Johanns, Jewel
    Szapary, Philippe
    Colombel, Jean-Frederic
    Targan, Stephan
    Ghosh, Subrata
    Sandborn, William J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S302 - S303
  • [39] Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy
    Sandborn, W. J.
    Rutgeerts, P.
    Gasink, C.
    Jacobstein, D.
    Zou, B.
    Johanns, J.
    Sands, B. E.
    Hanauer, S. B.
    Targan, S.
    Ghosh, S.
    de Villiers, W. J. S.
    Colombel, J. -F.
    Feagan, B. G.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 48 (01) : 65 - 77
  • [40] Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohn's Disease: The SEAVUE study
    Irving, P. M.
    Sands, B. E.
    Hoops, T.
    Izanec, J. L.
    Gao, L. L.
    Gasink, C.
    Greenspan, A.
    Allez, M.
    Danese, S.
    Hanauer, S. B.
    Jairatho, V.
    Kuchbacher, T.
    Lewis, J. D.
    Loftus, E. V., Jr.
    Mihaly, E.
    Panaccione, R.
    Scherl, E.
    Shchukina, O.
    Sandborn, W. J.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S001 - S002
12345